Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 5/20 | 0.51 |
| ▸ | CPB1 | P15086 | 1/20 | 0.50 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ANPEP | P15144 | 1/20 | 0.48 |
| ▸ | TGM2 | P21980 | 1/20 | 0.47 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25552109 | 0.90 | ANPEP (0.58) | FOLH1CPB1CPB2HTTANPEP | |
| SCHEMBL25552205 | 0.89 | CTSL (0.54) | FOLH1CPB1CPB2HTTMAPT | |
| SCHEMBL29832065 | 0.85 | MAPT (0.57) | FOLH1CPB1CPB2MAPT | |
| SCHEMBL16575045 | 0.81 | CPB1 (0.58) | FOLH1CPB1CPB2HTTANPEP | |
| SCHEMBL13471242 | 0.81 | FOLH1 (0.62) | FOLH1CPB1CPB2HTTTGM2 | |
| SCHEMBL9604544 | 0.81 | FOLH1 (0.62) | FOLH1CPB1CPB2HTTTGM2 | |
| SCHEMBL17250893 | 0.81 | FOLH1 (0.62) | FOLH1CPB1CPB2HTTTGM2 | |
| SCHEMBL31060114 | 0.81 | CPB1 (0.53) | FOLH1CPB1CPB2 | |
| SCHEMBL16575042 | 0.80 | HTT (0.55) | FOLH1CPB1CPB2HTTANPEP | |
| SCHEMBL16575040 | 0.80 | HTT (0.55) | FOLH1CPB1CPB2HTTANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207355-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF ANTICANCER DRUG | L-Base Co., Ltd. (KR) | 2024-06-27 | — | — | US | disclosed |
| US-20230159587-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER | L-Base Co., Ltd. (KR) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159587-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER | VIP, QPCT, TPT1 | FOLH1 193/4885CPB1 894/4885CPB2 1448/4885 |
| US-20240207355-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF ANTICANCER DRUG | ALPG, SLC11A2, SGTA | FOLH1 133/4885CPB1 2332/4885CPB2 3366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.